Lyra Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch LYRA and buy or sell other stocks, ETFs, and their options commission-free!

About LYRA

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. 

CEO
Maria Palasis
CEOMaria Palasis
Employees
30
Employees30
Headquarters
Watertown, Massachusetts
HeadquartersWatertown, Massachusetts
Founded
2005
Founded2005
Employees
30
Employees30

LYRA Key Statistics

Market cap
33.46M
Market cap33.46M
Price-Earnings ratio
-3.62
Price-Earnings ratio-3.62
Dividend yield
Dividend yield
Average volume
10.06M
Average volume10.06M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.344
52 Week high$0.344
52 Week low
$0.082
52 Week low$0.082

Stock Snapshot

As of today, Lyra Therapeutics(LYRA) shares are valued at $0.50. The company's market cap stands at 33.46M, with a P/E ratio of -3.62.

Lyra Therapeutics(LYRA) stock opened on 2026-03-18 at —. The price climbed to — and dipped to —.

Lyra Therapeutics(LYRA) shares are trading with a volume of 0, against a daily average of 10.06M.

In the last year, Lyra Therapeutics(LYRA) shares hit a 52-week high of $0.34 and a 52-week low of $0.08.

In the last year, Lyra Therapeutics(LYRA) shares hit a 52-week high of $0.34 and a 52-week low of $0.08.

People also own

Based on the portfolios of people who own LYRA. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.